Suven Life Sciences Ltd (Suven), a Hyderabad-based biopharmaceutical company focussed on discovering, developing and commercialising novel pharmaceutical products, has received five product patents for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The five granted product patents, one from China (CN 102869647), one from Israel (220709), one from Mexico (329382), one from Singapore (181992) and one from Sri Lanka (15412).

The claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of seventeen (17) granted patents from China, seven (7) granted patents from Israel, twenty (20) granted patents from Mexico, twenty one (21) granted patents from Singapore and eleven (11) granted patents from Sri Lanka. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.